Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-564
- Sponsors Merck Sharp & Dohme Corp.
- 02 Feb 2024 Results assessing patient-reported outcomes published in the Oncologist
- 27 Jan 2024 Interim results (data cutoff date: 15 Sep 2023) from the third prespecified interim analysis with a median follow-up of approx. 57 months presented at the 2024 Genitourinary Cancers Symposium
- 27 Jan 2024 According to Merck and Co media release , the company has announced results from the Phase 3 KEYNOTE-564 trial and the data has been presented during an oral session for the first time at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (abstract #LBA359) and are included in the official ASCO GU Press Program.